+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leukemia Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 130 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4591691
The Leukemia Therapeutics Market is expected to register a CAGR of 5.5% over the forecast period (2022-2027).

As most elective treatments were deferred due to the outbreak of the COVID-19 pandemic, the hematologic malignancies treatment was also impacted significantly. However, delayed treatment is not recommended for severe diseases, especially acute leukemia, and thus, necessary guidelines and measures have been put forth recently to allow leukemia treatments during the pandemic with all protective measures. According to the research article published in Karger Journal in October 2021, titled "Treating Leukemia in the Time of COVID-19" the risk of infection is low although the mortality may be higher in patients with leukemia and COVID-19. Additionally, as per the research study "Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak" published in Cancer Discovery in June 2021, the risk of experiencing severe cases of COVID-19 infection was found to be higher, at about 57%, among patients with blood cancers. Thus, given the aforementioned factors, the COVID-19 pandemic is expected to impact the growth of the studied market.

The leukemia therapeutics market is mainly driven by the rising burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in healthcare sectors. A significant number of population across the globe suffers from leukemia. For instance, as per the statistics by the GLOBOCAN 2020, leukemia accounted for 474, 519 cases for both sexes of all ages in 2020, worldwide. As per the same above-mentioned source, 311,594 number of deaths occurred in 2020 due to leukemia, worldwide. In addition, as per the 2021 statistics by the Leukemia & Lymphoma Society, an estimated 397,501 people are living with or in remission from leukemia in the United States. Hence, the overall statistics shows that there is a huge number of people that are prone to suffer from leukemia, and which may directly impact the growth of the market in the forecast period.

Furthermore, the increasing number of investments being made on research and development has enabled several pharmaceutical and biotechnology companies to focus and develop novel and effective drugs. For instance, in April 2021, the Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP) reported five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers. LLS has dedicated more than USD 100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.

However, high cost of treatment and stringent regulatory scenario restraint the market growth over the forecast period.

Key Market Trends

Chemotherapy is Expected to Register a Significant Growth Over the Forecast Year

Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells in the body. Chemotherapy is most often used to treat cancer since cancer cells grow and multiply much more quickly than most cells in the body.

The primary key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. According to the American Cancer Society, in 2019, there was around 22,840 death from leukemia in the United States, which has been reported and one of the leading to the overall growth of the market. Also, as per the 2021 statistics by the Blood Cancer UK, although rare, children can develop acute myeloid leukemia (AML). As per the same above-mentioned source, in the United Kingdom, around 100 children a year are diagnosed with the condition.

Many companies are also focusing on developing breakthrough products for the treatment of Leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy is thus considered the main treatment option for most individuals with Leukemia. For instance, in December 2021, BDR Pharma has launched India’s one of the first Generic- Midostaurin under the brand name MSTARIN, Midostaurin single-agent maintenance therapy for adults with newly diagnosed Leukemia who are FLT3 mutation-positive.

Additionally, the increase in funding for companies involved in the research related to leukemia is expected to boost the studied market.

North America Holds the Large Share in the Leukemia Therapeutics Market Over the Forecast Period

the North American region holds a large share in the leukemia therapeutics market due to the presence of high incidence rate, and advancements in the treatment of leukemia. According to American Cancer Society estimates in January 2022, about 60,650 new cases of leukemia and 24,000 deaths from leukemia and there were around 11,450 deaths due to acute myeloid leukemia in the United States in the year 2022. The statistics involve a large percentage of the adult population and they require proper medical treatment to increase their life expectancy.

According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. ​ Thus, the increasing number of leukemia cases in the region is a major driving factor for the growth of the market.

Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to drive market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly USD 17 million research grants, to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers. Furthermore, in December 2020, Jazz Pharmaceuticals submitted the Biologics License Application (BLA) for its JZP-458 for use as a component of a multiagent chemotherapy regimen in the treatment of patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).

Thus, due to the above-mentioned developments, the market is expected to see robust growth.​

Competitive Landscape

The leukemia therapeutics market is competitive and many of the global players are into the market. Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market. Some of the major players in the market are Amgen Inc, AstraZeneca plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Novartis, Pfizer Inc and Sanofi. are providing these products across the globe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Leukemia Cases
4.2.2 High Unmet Need for Cancer Therapy
4.2.3 Rising Investment in Healthcare Sector
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Stringent Regulatory Scenario
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Immunotherapy
5.1.3 Targeted Therapy
5.1.4 Others
5.2 By Type of Leukemia
5.2.1 Acute Lymphocytic Leukemia
5.2.2 Acute Myeloid Leukemia
5.2.3 Chronic Lymphocytic Leukemia
5.2.4 Chronic Myeloid Leukemia
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 AstraZeneca plc
6.1.3 Bristol-Myers Squibb Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Incyte Corp
6.1.6 Johnson & Johnson
6.1.7 Novartis International AG
6.1.8 Pfizer Inc.
6.1.9 Sanofi S.A.
6.1.10 Teva Pharmaceutical
6.1.11 Astellas Pharma
6.1.12 Otsuka Holdings Co., Ltd

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical
  • Astellas Pharma
  • Otsuka Holdings Co., Ltd